Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology hosted its Q4 and full-year 2025 earnings call on March 9, 2026, with CEO Denny Lanfear, CDO Theresa Lavallee, CMO Rosh Dias, CCO Sameer Goregaoker and CFO Bryan McMichael participating. The provided excerpt contains the call introduction and standard forward-looking statement directing listeners to the press release and Form 10-K for risks. No financial results, guidance, or material operational updates were included in the excerpt.

Analysis

Coherus’ profile (small-cap oncology/biosimilar-oriented franchise) benefits disproportionately from structural supply-side constraints in sterile biologics manufacturing and specialty-channel distribution. Limited incremental manufacturing capacity and high switching friction at infusion centers create a moat that can convert modest volume gains into outsized margin expansion over 6–24 months, especially if peers struggle with fill/finish or quality inspections.

Near-term catalysts that matter are commercial snap-points (payer contracting windows, hospital formulary re-negotiations, and any CMS Part B reimbursement adjustments) rather than headline trial data. These events operate on a cadence of weeks-to-months and can swing realized pricing by mid-single digits to low-double-digits — enough to change 12-month revenue trajectories materially for a company already near breakeven on incremental margin.

Key tail risks are financing/dilution and systemic risk in small-cap biotech flows: high rates and bank/credit strain compress coverage and push institutions to de-risk, which can move a stock multiple faster than fundamentals for 1–3 quarters. Another non-obvious reversal is rapid competitive entry driven by a single competitor clearing regulatory or inspection backlogs — a shock that would pressure pricing within 60–180 days.

The highest-conviction read is asymmetric idiosyncratic upside if management can lock incremental formulary wins while preserving margin; downside is concentrated into catalyst windows and broad market risk. Trading should therefore be event-aware and hedged; ownership as a concentrated directional position is sensible only with explicit option-based downside protection or a correlated macro hedge to protect against a liquidity-driven derating.

Key Decisions for Investors

• Long CHRS equity with options hedge: initiate a 6–12 month position equal to 2–4% of NAV in CHRS stock and simultaneously buy 3–6 month 25-delta puts sized to limit downside to ~30% of the position notional (target asymmetry: +50–150% upside vs -30% downside over 6–12 months). Rationale: capture formulary/pricing wins while protecting vs a liquidity-driven derate.
• Call-spread tactical trade: buy 9–12 month 25-delta CHRS calls and sell 9–12 month higher-strike calls (10–15% OTM) to fund premium — target net debit ~50–70% of long-call cost. Time entry into windows 2–6 weeks before known payer contracting or commercial cadence to capture re-rating while capping premium at acceptable loss.
• Event pair hedge vs systemic risk (using JPM): if holding CHRS into uncertain market periods, buy 3-month JPM puts (or a short JPM position equal to 25–40% of CHRS notional) as a cheap hedge against a sudden risk-off that typically hits small-cap biotech hardest. Expect this hedge to cost <2% annualized but to protect against multi-week liquidity shocks.
• Short volatility / take-profit plan: if CHRS rallies >40% in a single month after a commercial win, trim to target allocation and sell near-term calls to monetize implied vol — lock gains because rapid repricing is often followed by profit-taking when headlines cool (timeframe: 2–8 weeks after move).